Oncology

A new partnership aims to accelerate a pipeline of innovative multi-functional fusion proteins, potentially reshaping treatment for cancer and autoimmune disease.

Privo Technologies reports its PRV211 patch was well-tolerated in a key trial, offering a new, localized approach to preventing oral cancer recurrence.

With promising results in tough-to-treat colorectal cancer, a strong cash runway, and key alliances, Adagene is poised for a pivotal year.

Ontario's new FAST program provides accelerated funding for two key cancer drugs, cutting patient wait times and setting a new standard for access in Canada.

London's Ellipses Pharma in-licenses a novel B7H3 antibody-drug conjugate from Innolake, aiming to outmaneuver competitors with a unique payload.

PAQ Therapeutics advances its pan-KRAS degrader into human trials, backed by a $77M funding round, offering new hope for notoriously tough cancers.

A new, self-administered RNA therapy for hereditary angioedema gains EU approval, promising fewer attacks and greater freedom for thousands of patients.

HT Vet's new VISTA iQ uses AI to screen dog lumps in 40 seconds, aiming to save lives and transform the financial health of veterinary practices.

The global CRO is acquiring specialized firm Catalyst Clinical Research, aiming to dominate the booming oncology trial market. But can it navigate the risks?

For 10 years, McKesson's QCDR has helped oncologists navigate MIPS. Now, new measures aim to elevate patient care and prove the value of treatment.

GSK's subsidiary Tesaro inks a deal worth up to $285M with Alteogen to create an under-the-skin version of its cancer drug Jemperli.

The world's top cancer center partners with IBA in a multi-million dollar deal to install three advanced Proteus®ONE systems, heralding a new era.

At a major San Francisco summit, Chinese biotechs unveiled breakthrough heart and cancer drugs, signaling a strategic shift from manufacturing to global innovation.

New legislation, SB 1165, could save lives by eliminating out-of-pocket costs for diagnostic breast imaging, a financial burden forcing many to delay care.

Vaximm appoints Sébastien Wieckowski as CSO, leveraging his data science expertise to advance its oral cancer vaccine platform at a pivotal clinical stage.

A first-in-class immunotherapy, UNLOXCYT™, offers a new lifeline for patients with advanced skin cancer, made accessible through a key national partnership.

Profusa launches its Lumee system for research, aiming to capture a piece of the $47B CRO market and revolutionize drug development with real-time data.

The global digital immunoassay market is set to triple, promising to find diseases earlier than ever. But can healthcare systems overcome the high cost?

With its lead drug in human trials, ViroMissile hires a seasoned CBO to navigate the competitive oncolytic virus market and secure its future.

A new partnership aims to make life-saving cancer and anti-infective drugs stable at room temperature, revolutionizing global access and sustainability.